financetom
Business
financetom
/
Business
/
What's Going On With ImmunityBio Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With ImmunityBio Stock?
Apr 26, 2024 12:44 PM

ImmunityBio, Inc. ( IBRX ) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study.

The Details:

ImmunityBio ( IBRX ) said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy. 

"The results we noted with the completion of the QUILT 3.055 basket trial across multiple tumor types in patients with late-stage cancers for whom standard of care plus checkpoints failed, validates our hypothesis that orchestration of NK cells with killer T cells and memory T cells could result in meaningful clinical improvements to current standards of care," said Patrick Soon-Shiong, M.D., CSO of ImmunityBio ( IBRX ). 

The FDA approved the company's Anktiva plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on Monday. 

ImmunityBio ( IBRX ) shares are moving on heavy trading volume Friday. According to data from Benzinga Pro, more than 26.6 million shares have been traded in the session, compared to the stock’s 100-day average of 4.774 million shares.

Related News: What’s Going On With Luxury EV-Maker Lucid’s Stock?

How To Buy IBRX Stock:

By now you're likely curious about how to participate in the market for ImmunityBio ( IBRX ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

IBRX Price Action: According to Benzinga Pro, ImmunityBio ( IBRX ) shares are up 48% at $7.56 at the time of publication Friday.

Image: Akava Photo from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blackstone offers to take Japan's TechnoPro private for $3.5 billion
Blackstone offers to take Japan's TechnoPro private for $3.5 billion
Aug 6, 2025
TOKYO, Aug 6 (Reuters) - Blackstone said on Wednesday that it will launch a $3.5 billion tender offer for TechnoPro Holdings ( TXHPF ), the Japanese engineer staffing firm. The world's largest alternative asset manager is offering 507.4 billion yen or 4,870 yen per a share - a 17.4% premium to the share's closing average for the past three months....
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Wix.com Q2 Non-GAAP Earnings, Revenue Rise; Raises 2025 Revenue Guidance
Wix.com Q2 Non-GAAP Earnings, Revenue Rise; Raises 2025 Revenue Guidance
Aug 6, 2025
03:47 AM EDT, 08/06/2025 (MT Newswires) -- Wix.com ( WIX ) reported Q2 non-GAAP earnings Wednesday of $2.28 per diluted share, up from $1.67 a year earlier. Analysts polled by FactSet expected $1.75. Revenue for the quarter ended June 30 was $489.9 million, compared with $435.7 million a year earlier. Analysts surveyed by FactSet expected $487.3 million. For Q3, the...
Innospec Q2 Adjusted Earnings Fall, Revenue Rises
Innospec Q2 Adjusted Earnings Fall, Revenue Rises
Aug 6, 2025
03:50 AM EDT, 08/06/2025 (MT Newswires) -- Innospec ( IOSP ) reported Q2 adjusted earnings late Tuesday of $1.26 per diluted share, down from $1.39 a year earlier. Two analysts polled by FactSet expected $1.21. Revenue for the quarter ended June 30 was $439.7 million, compared with $435 million a year earlier. Two analysts surveyed by FactSet expected $433.3 million....
Copyright 2023-2026 - www.financetom.com All Rights Reserved